Exome Asset Management LLC
Exome Asset Management LLC reported 52 US-listed holdings worth $162.1 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Guardant Health, Inc. (6.2%), Praxis Precision Medicines I (5.6%) and TG Therapeutics, Inc. (5.6%). Against the quarter before, it opened 15 positions, added to 1, trimmed 32 and sold out of 8.
Reported holdings$162.1M-4.6% on Q1 2026
Positions52+7 on Q1 2026
The largest ten44.6%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedTrimmed
The 14 largest of its 52 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +216.6% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 15Added 1Held 4Trimmed 32Sold out 8
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 15
- TG Therapeutics, Inc. TGTX$9.1 million
- Abivax SA ABVX$6.2 million
- Uniqure NV QURE$3.7 million
- AstraZeneca PLC AZN$2.3 million
- Viking Therapeutics, Inc. VKTX$1.9 million
- Ocular Therapeutix Inc. OCUL$1.8 million
- Equillium Inc. EQ$1.8 million
- Ascendis Pharma A/s ASND$1.8 million
and 7 more in the table below
Added to 1
- Maze Therapeutics, Inc. MAZE+26,182 shares · +30%
Trimmed 32
- Praxis Precision Medicines I PRAX-18,264 shares · -40%
- Enliven Therapeutics Inc. ELVN-119,888 shares · -54%
- Relay Therapeutics, Inc. RLAY-230,771 shares · -83%
- Cytokinetics Inc. CYTK-43,662 shares · -42%
- BridgeBio Pharma, Inc. BBIO-49,133 shares · -73%
- Cogent Biosciences Inc. COGT-68,010 shares · -24%
- Guardant Health, Inc. GH-15,236 shares · -18%
- Alumis Inc. ALMS-74,758 shares · -27%
and 24 more in the table below
Sold out of 8
- Elevance Health, Inc. ELV$4.3 million last quarter
- Apellis Pharmaceuticals Inc. APLS$3.4 million last quarter
- Avalo Therapeutics Inc. AVTX$2.4 million last quarter
- Soleno Therapeutics Inc. SLNO$2.1 million last quarter
- 4D Molecular Therapeutics in FDMT$1.2 million last quarter
- Nextcure Inc. NXTC$1.2 million last quarter
- Palisade Bio Inc. PALI$1.1 million last quarter
- Lipocine Inc. New LPCN$486,279 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Guardant Health, Inc. GH | 67.5K | $10.1 million | 6.25% | -15.2K |
| Praxis Precision Medicines I PRAX | 27.2K | $9.1 million | 5.62% | -18.3K |
| TG Therapeutics, Inc. TGTX | 164.9K | $9.1 million | 5.59% | new |
| Cogent Biosciences Inc. COGT | 210.5K | $8.1 million | 5.03% | -68.0K |
| Ionis Pharmaceuticals Inc. IONS | 88.2K | $7.0 million | 4.31% | -21.9K |
| Eli Lilly & Co. LLY | 5.5K | $6.6 million | 4.06% | -1.5K |
| Abivax SA ABVX | 46.9K | $6.2 million | 3.85% | new |
| Alumis Inc. ALMS | 204.4K | $5.8 million | 3.55% | -74.8K |
| Cytokinetics Inc. CYTK | 60.1K | $5.1 million | 3.16% | -43.7K |
| Enliven Therapeutics Inc. ELVN | 100.2K | $5.1 million | 3.14% | -119.9K |
| Vera Therapeutics Inc. VERA | 97.3K | $4.2 million | 2.57% | -17.7K |
| UnitedHealth Group Inc. UNH | 9.6K | $4.0 million | 2.46% | -3.2K |
| 10x Genomics, Inc. TXG | 102.6K | $3.9 million | 2.43% | -51.6K |
| Natera, Inc. NTRA | 13.8K | $3.7 million | 2.31% | -4.8K |
| Uniqure NV QURE | 81.1K | $3.7 million | 2.30% | new |
| Rhythm Pharmaceuticals, Inc. RYTM | 32.2K | $3.6 million | 2.21% | -8.4K |
| Maze Therapeutics, Inc. MAZE | 114.7K | $3.4 million | 2.11% | +26.2K |
| Monte Rosa Therapeutics Inc. GLUE | 137.1K | $3.3 million | 2.05% | -42.4K |
| Moonlake Immunotherapeutics MLTX | 166.5K | $3.2 million | 2.00% | -48.9K |
| Alkermes plc. ALKS | 61.3K | $3.2 million | 1.98% | -22.8K |
| Liquidia Corp. LQDA | 39.2K | $3.1 million | 1.93% | -6.6K |
| United Therapeutics Corp. UTHR | 5.4K | $2.9 million | 1.81% | -1.6K |
| Glaukos Corp. GKOS | 19.9K | $2.8 million | 1.71% | -1.0K |
| Arrowhead Pharmaceuticals, Inc. ARWR | 32.2K | $2.6 million | 1.62% | -13.5K |
| Agios Pharmaceuticals, Inc. AGIO | 70.5K | $2.6 million | 1.61% | -54.6K |
| Crescent Biopharma Inc. CBIO | 127.8K | $2.3 million | 1.42% | -25.4K |
| AstraZeneca PLC AZN | 12.0K | $2.3 million | 1.39% | new |
| Boston Scientific Corp. BSX | 48.3K | $2.1 million | 1.27% | no change |
| Adagene Inc. ADAG | 488.3K | $2.1 million | 1.27% | -248.6K |
| Penumbra Inc. PEN | 6.3K | $2.0 million | 1.23% | no change |
| Intuitive Surgical Inc. ISRG | 4.9K | $2.0 million | 1.20% | -1.4K |
| Viking Therapeutics, Inc. VKTX | 47.9K | $1.9 million | 1.15% | new |
| Ocular Therapeutix Inc. OCUL | 181.6K | $1.8 million | 1.10% | new |
| Equillium Inc. EQ | 553.0K | $1.8 million | 1.09% | new |
| Ascendis Pharma A/s ASND | 6.6K | $1.8 million | 1.08% | new |
| Corbus Pharmaceuticals Hldgs CRBP | 184.9K | $1.7 million | 1.07% | -49.2K |
| Cytomx Therapeutics Inc. CTMX | 460.1K | $1.7 million | 1.06% | -61.4K |
| Verastem Inc. VSTM | 429.0K | $1.6 million | 1.01% | -207.7K |
| Nektar Therapeutics NKTR | 22.4K | $1.6 million | 0.97% | new |
| Clearpoint Neuro Inc. CLPT | 83.6K | $1.5 million | 0.92% | new |
| Insmed Inc. INSM | 13.9K | $1.5 million | 0.91% | -12.8K |
| Caris Life Sciences, Inc. CAI | 78.2K | $1.4 million | 0.86% | new |
| BridgeBio Pharma, Inc. BBIO | 18.4K | $1.4 million | 0.84% | -49.1K |
| Zenas BioPharma, Inc. ZBIO | 52.4K | $1.3 million | 0.82% | -28.3K |
| I Mab NBP | 577.0K | $1.1 million | 0.69% | no change |
| Establishment Labs Holdings Inc. ESTA | 13.1K | $1.1 million | 0.69% | no change |
| Relay Therapeutics, Inc. RLAY | 47.5K | $889,305 | 0.55% | -230.8K |
| Geron Corp. GERN | 624.0K | $798,779 | 0.49% | new |
| Bright Minds Biosciences Inc. DRUG | 10.1K | $709,722 | 0.44% | new |
| Compass Therapeutics Inc. CMPX | 276.2K | $604,801 | 0.37% | new |
| Replimune Group, Inc. REPL | 40.4K | $446,796 | 0.28% | new |
| Arbutus Biopharma Corp. ABUS | 50.2K | $240,797 | 0.15% | -25.3K |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.